These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 15023160)

  • 1. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients.
    Hamdy AF; Bakr MA; Ghoneim MA
    J Am Soc Nephrol; 2008 Jun; 19(6):1225-32. PubMed ID: 18337483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diarrhea after kidney transplantation: A study of risk factors and outcomes.
    Patil AD; Saxena NG; Thakare SB; Pajai AE; Bajpai D; Jamale TE
    J Postgrad Med; 2023; 69(4):205-214. PubMed ID: 37675667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis.
    Almeida CC; Silveira MR; de Araújo VE; de Lemos LL; de Oliveira Costa J; Reis CA; de Assis Acurcio F; das Gracas Braga Ceccato M
    Pharmaceuticals (Basel); 2013 Sep; 6(10):1170-94. PubMed ID: 24275847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KidneyCare Guided Immuno-Optimization in Renal Allografts: The KIRA Protocol.
    Gray JN; Wolf-Doty T; Sulejmani N; Gaber O; Axelrod D; Abdalla B; Danovitch G
    Methods Protoc; 2020 Sep; 3(4):. PubMed ID: 33007896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
    Deng J; Lu Y; He L; Ou J; Xie H
    Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
    Karpe KM; Talaulikar GS; Walters GD
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.
    Yan TZ; Wu XQ; Rong L
    SAGE Open Med; 2016; 4():2050312116643672. PubMed ID: 27231549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.
    Mathis AS; Egloff G; Ghin HL
    World J Transplant; 2014 Jun; 4(2):57-80. PubMed ID: 25032096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time to give up with calcineurin inhibitors in kidney transplantation?
    Salvadori M; Bertoni E
    World J Transplant; 2013 Jun; 3(2):7-25. PubMed ID: 24175203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.
    Golshayan D; Pascual M; Vogt B
    Ther Clin Risk Manag; 2009 Aug; 5(4):341-51. PubMed ID: 19753127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to sirolimus of patients with chronic allograft nephropathy--a retrospective analysis of outcome and influencing factors.
    Witzke O; Viklicky O; Türk TR; Lutz J; Wilde B; Willenberg I; Vitko S; Heemann U
    Langenbecks Arch Surg; 2009 Nov; 394(6):1073-8. PubMed ID: 19020895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus.
    Kreijveld E; Koenen HJ; van Cranenbroek B; van Rijssen E; Joosten I; Hilbrands LB
    PLoS One; 2008 Jul; 3(7):e2711. PubMed ID: 18628993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.
    Earnshaw SR; Graham CN; Irish WD; Sato R; Schnitzler MA
    J Am Soc Nephrol; 2008 Sep; 19(9):1807-16. PubMed ID: 18562571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.
    Srinivas TR; Meier-Kriesche HU
    Clin J Am Soc Nephrol; 2008 Mar; 3 Suppl 2(Suppl 2):S101-16. PubMed ID: 18308998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of renal function in heart transplant children.
    Di Filippo S; Cochat P; Bozio A
    Pediatr Nephrol; 2007 Mar; 22(3):333-42. PubMed ID: 16932899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.
    Merville P
    Drugs; 2005; 65(5):615-31. PubMed ID: 15748097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy.
    Suwelack B; Gerhardt U; Hohage H
    Am J Transplant; 2004 Apr; 4(4):655-62. PubMed ID: 15023160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.